{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:27:40Z","timestamp":1790868460639,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CLIN INFECT DIS"],"published-print":{"date-parts":[[1999,1]]},"DOI":"10.1086\/515086","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T20:08:02Z","timestamp":1196798882000},"page":"49-51","source":"Crossref","is-referenced-by-count":52,"title":["Editorial Response: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis"],"prefix":"10.1093","volume":"28","author":[{"given":"Jonathan\u00a0D.","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/28\/1\/49\/857657\/28-1-49.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T17:10:56Z","timestamp":1503421856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/515086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1086\/515086"],"URL":"https:\/\/doi.org\/10.1086\/515086","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}